Anastrozole (Arimidex)

From - A Hematology Oncology Wiki
Jump to navigation Jump to search

General information

Class/mechanism: Selective non-steroidal aromatase inhibitor. The aromatase enzyme converts adrenal and ovarian androgens (androstenedione and testosterone) to estrogens (estrone and estradiol) in peripheral tissues.[1][2][3]
Route: PO
Extravasation: n/a

For conciseness and simplicity, currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, UpToDate Lexidrug, Medscape, or the prescribing information.[1]

Diseases for which it is used

Patient drug information

History of changes in FDA indication

History of changes in EMA indication

The approval of this drug pre-dates the EMA.

  • 1995-08-11: EURD

History of changes in Health Canada indication

  • 2004-06-30: Initial notice of compliance with conditions
  • 2008-12-02: Conditions were met

Also known as

  • Brand names: Altraz, Anabrez, Anastraze, Anastrazol Rontag, Anastrol, Arimidex, Asiolex, Karomex, Leprofen, RUI SI YI, RUI Ting, Trozolet, Trozolite.